J 2016

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

SZTURZ, Petr, Pol SPECENIER, Carl VAN LAER, Danielle VAN DEN WEYNGAERT, Bob CORTHOUTS et. al.

Základní údaje

Originální název

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

Autoři

SZTURZ, Petr (203 Česká republika, garant, domácí), Pol SPECENIER (56 Belgie), Carl VAN LAER (56 Belgie), Danielle VAN DEN WEYNGAERT (56 Belgie), Bob CORTHOUTS (56 Belgie), Laurens CARP (56 Belgie), Eric VAN MARCK (56 Belgie), Olivier VANDERVEKEN (56 Belgie) a Jan B. VERMORKEN (56 Belgie)

Vydání

European Archives of Oto-Rhino-Laryngology and Head & Neck, NEW YORK, SPRINGER, 2016, 0937-4477

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.660

Kód RIV

RIV/00216224:14110/16:00090827

Organizační jednotka

Lékařská fakulta

UT WoS

000375607700038

Klíčová slova anglicky

Tonsil cancer; Positron emission tomography; Taxanes; Targeted therapy; Epidermal growth factor receptor inhibitor

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 15. 9. 2016 15:20, Soňa Böhmová

Anotace

V originále

In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.